Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 21Unknown 9Terminated 4Recruiting 4Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 19Sarcoma 1Other solid neoplasm 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Gynecologic 1Gastrointestinal 1Endocrine 1Dermatologic 1CNS 1

Conditions

Ovarian Neoplasms 1

Interventions

Paclitaxel 24Carboplatin 18Bevacizumab 14Cisplatin 10pembrolizumab 7fluzoparib 7Radiotherapy 6Drug Therapy 6apatinib 5Topotecan 5Magnetic Resonance Spectroscopy 5Injections 5liposomal doxorubicin 4lenvatinib 4famitinib 4camrelizumab 4Tirzepatide 4Specimen Handling 4Platinum 4Observation 4Gemcitabine 4Brachytherapy 4toripalimab 3olaparib 3dostarlimab 3anlotinib 3Watchful Waiting 3Therapeutics 3Surveys and Questionnaires 3Neoadjuvant Therapy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Etoposide × Gynecologic × Clear all
NCT07117877 2025-08-28

Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian Cancer

Fudan University

Phase 2 Not yet recruiting
33 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡